Hepatocyte Transplantation / 대한이식학회지

ABSTRACT

Since the first hepatocyte transplantation (HT) was done by Matas and colleagues 3 decades ago in Gunn rats, there has been much development in the field of HT and clinical application to over 70 humans has been performed worldwide ever since. HT has many advantages compared to the conventional liver transplantation (LT) such as lower cost, lower morbidity, possibility of genetic modification, availability of cryopreservation, utilization of inadequate livers for LT and possibility to transplant to multiple recipients from a single donor. HT has been applied as a definitive treatment option in metabolic liver disease or fulminant hepatic failure with marginal results. It has also been used as a bridge to LT in severely ill patients awaiting LT, but it has not yet been widely accepted due to the shortcoming of clinical efficacy compared to LT. Much effort was made over the past several years to improve these results, and we hope that with the help of future research, HT will soon have a clear clinical role in the management of liver diseases. This review article will cover various animal models used for researching HT and methods used for transplanting hepatocytes. It will also briefly introduce the worldwide clinical results in human trials as well as our experience on a successful case with glycogen storage disease and its long term result.